Skip to main content

Table 2 Adverse events reported at the 1-year follow-up examination

From: Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial

  Abatacept (n = 43) Rituximab (n = 46) TNFi (n = 50) Total (n = 139)
  Number of events Number of patients Number of events Number of patients Number of events Number of patients Number of events Number of patients
Cardiovascular event 1 1 2 2 2 2 5 5
Infection 9 6 5 4 11 7 25 18
Malignancy 0 0 3 3 0 0 3 3
Laboratory abnormalitiesa 1 1 0 0 2 2 3 3
Skin condition 3 3 3 3 6 5 12 11
Gastroenterological 2 2 3 3 0 0 5 5
Otherb 5 4 7 5 7 4 19 13
Total 21 16 23 15 28 20 78 51
  1. aLiver function test elevations and leukopenia. bIn this group, the adverse effects consisted primarily of influenza, fever, fatigue, headache and/or dizziness. One patient in the abatacept group developed psychosis 4 months after the start of the study.